PathAI AISight

by PathAI

🟢Active

A cloud-based digital pathology image management system from PathAI for viewing, managing, and sharing whole-slide images and associated case data, with support for research workflows and AI applications.

HealthcareFounded by Andy Beck and Aditya KhoslaVisit website →
🔍 Last checked: 8/29/2026 · Confidence: 91%

Why Abandoned

PathAI currently maintains an AISight product page and announced AISight DX as FDA-cleared for primary diagnosis in the United States in 2023. No verified shutdown or acquisition of the product was found.

🩺 Health Signals

3d ago
HTTP Status
200
Response
SSL
Confidence
91%
Domain expires
Last content change
Last tweet
API status

📅 Timeline

2021-07-27

AISight launched

PathAI introduced AISight as a cloud-based digital pathology platform designed to support slide viewing, image management, collaboration, and AI-powered pathology workflows.

2021-11-04

PathAI acquired Poplar Healthcare

PathAI acquired Poplar Healthcare, a pathology laboratory services company, expanding its clinical diagnostics operations and access to pathology workflow expertise.

2022-10-13

AISight received CE marking

PathAI announced CE marking for AISight as a medical device for primary diagnosis in the European Economic Area.

2023-09-05

AISight DX received FDA clearance

PathAI announced FDA 510(k) clearance for AISight DX as a digital pathology image management system for primary diagnosis in the United States.

🔄 Alternatives to PathAI AISight

🪦 Other dead Healthcare tools

Frequently Asked Questions

What is PathAI AISight?

PathAI AISight is a cloud-based digital pathology platform used to view, organize, manage, and share digitized pathology slides and related case information.

What is PathAI AISight used for?

Pathology laboratories and research teams use AISight for whole-slide image review, case collaboration, image and data management, and access to compatible computational pathology applications.

Is PathAI AISight FDA cleared?

PathAI announced in September 2023 that AISight DX received FDA 510(k) clearance as a digital pathology image management system for primary diagnosis in the United States.

Can PathAI AISight be used for primary diagnosis?

The regulated AISight DX configuration is cleared in the United States for primary diagnosis when used according to its FDA-cleared indications, supported scanners, displays, and labeling. Availability and permitted use can vary by jurisdiction.

Who owns and develops PathAI AISight?

AISight is developed and offered by PathAI, a Boston-based company founded by Andy Beck and Aditya Khosla that builds AI and digital pathology products for biopharma and diagnostic laboratories.